Benitec Biopharma Inc. — Form 10-K
Filed September 14, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 8/100
What the filing says
Benitec amended its insider trading policy effective May 12, 2026, establishing blackout periods around quarterly earnings announcements, pre-clearance requirements for Section 16 officers and designated key employees, and prohibitions on hedging, short-selling, and derivative transactions. The policy covers all employees, directors, and consultants with access to material nonpublic information. No counterparties, dollar amounts, or share counts are specified—this is a routine governance document outlining compliance procedures.
Why this rating
Routine policy update with standard anti-insider-trading provisions; administrative in nature. No material business impact, no transactions disclosed, no financial change to company operations or position. Standard for public companies.
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.